A groundbreaking clinical trial focusing on migraine therapy highlights the potential of combining manual therapy with myotensive extraocular muscle techniques to address migraine without aura.
In this article
- What is the trial about?
- What interventions are being tested?
- Who may benefit?
- More questions answered
- Conclusion and next steps
- Disclaimer
- Announcement and original source
What is the trial about?
The Facultad de Enfermería, Fisioterapia y Podología (FEFP) is sponsoring a novel clinical trial investigating the role of advanced manual therapy techniques for patients suffering from migraine without aura. This study is detailed on ClinicalTrials.gov, registered under the identifier NCT07254598. As of now, the study is not yet recruiting participants.
Migraine without aura impacts millions globally, causing significant disruptions to daily life. This study aims to determine whether combining myotensive extraocular muscle techniques with conventional manual therapy can enhance treatment outcomes.
What interventions are being tested?
Two intervention groups are planned for comparison:
- Group 1: Patients will receive a combination of manual therapy and myotensive extraocular muscle techniques.
- Group 2: Patients will receive standard manual therapy without the addition of myotensive techniques.
The myotensive extraocular muscle techniques aim to regulate eye muscle tension, potentially impacting factors associated with migraines. Manual therapy, widely used in physiotherapy, focuses on joint mobilizations, massage, and other physical manipulations to alleviate symptoms.
Researchers will monitor various outcome measures to establish safety, performance, and therapeutic effectiveness of the combined approach.
Who may benefit?
If proven effective, the trial could open new avenues for individuals with migraine without aura, especially those with limited response to existing therapies. This investigation is particularly relevant to clinicians working in neurology, physiotherapy, and pain management fields.
The study design aligns with regulatory expectations for clinical evidence under frameworks such as MDR Annex XIV. Careful documentation of patient outcomes and adverse events will be critical to assessing safety and efficacy.
Frequently Asked Questions
- 1. What is the current recruitment status?
The trial is not yet recruiting participants as of November 29, 2025. - 2. Where can I find the trial’s official details?
The official record is available on ClinicalTrials.gov under identifier NCT07254598. - 3. Are the interventions considered medical devices?
The trial focuses on technique-based therapies rather than standalone devices. However, regulatory implications could involve MDR medical fields. - 4. Is this therapy available for general use?
No. The combination of techniques is under investigation and not yet available as a validated treatment.
Conclusion and next steps
The FEFP-led trial highlights the push for innovative treatments in managing migraines without aura. While the research is in its pre-recruitment phase, stakeholders within clinical and regulatory sectors should monitor progress and assess potential applications.
Updates will follow as the trial commences and offers valuable insights into optimizing migraine interventions.
Disclaimer
This article is for informational purposes only and does not constitute professional or legal advice. Please refer to qualified medical and regulatory professionals for specific guidance.
Announcement and original source
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07254598?term=medical+device